A Review of Eales' Disease and Mycobacterium tuberculosis.

Simple Summary: Eales' Disease, an ocular condition characterized by unknown pathophysiology, exhibits a higher prevalence among young males. Since the etiology of the disease remains unclear, a comprehensive exploration of clinical presentations and diagnostic approaches is undertaken to deepen insights into its current understanding. Furthermore, potential cofactors that may trigger Eales' Disease are reviewed, investigating the association between Eales' Disease and other ocular conditions such as diabetic retinopathy and glaucoma. Additionally, diverse therapeutic interventions across disease stages are examined to assess the efficacy and possibility of repurposing treatments from related conditions. Through this review, the aim is to extend and elucidate potential study areas to facilitate a comprehensive understanding of Eales' Disease and aid patients in preventing the disease or finding optimal treatment strategies. Eales' Disease is an idiopathic peripheral retinal vasculopathy first described by British ophthalmologist Henry Eales in 1880. Most prevalent in healthy young males, Eales' Disease often presents with symptoms of sudden blurry or decreased vision and floaters. Although no clear, standardized stage of the disease exists, it progresses through three overlapping phases—peripheral periphlebitis, ischemic capillary ischemia, and retinal neovascularization. The etiology of Eales' Disease is unknown and appears to be multifactorial, but post-TB hypersensitivity to tuberculoprotein and M. tuberculosis DNA is the most potential cause in the etiology of Eales' Disease. With a thorough examination of the clinical presentation and diagnosis of Eales' Disease—incorporating the latest clinical findings related to the condition—the investigation for Eales' Disease extends to explore recent potential connections with other ocular conditions or possible cofactors, such as glaucoma, uncontrolled diabetes, drug abuse, or inherited medical conditions. Moreover, focusing on critical insights into the treatment of Eales' Disease across its various stages of progression, the overarching goal of the paper is to refine and suggest possible future diagnostic and therapeutic strategies. Widening our understanding of pathophysiology and utilizing various treatment options for individual patients holds immense potential for advancing ocular medicine and optimizing patient care for people with this disease with unknown pathophysiology. [ABSTRACT FROM AUTHOR]